Introduction {#h0.0}
============

AppA from *Rhodobacter sphaeroides* ([@B1]) is a blue-light photoreceptor discovered a decade ago that utilizes flavin as a chromophore. It is among the first identified members of a broadly disseminated BLUF (sensors of *b*lue *l*ight *u*sing *F*AD) family of photoreceptors ([@B2]). Since their identification, there has been extensive research on the BLUF photocycle providing significant insight on how light absorption by a bound flavin leads to a conformational change in the BLUF domain ([@B3]). In many cases, it remains unclear how light-driven alterations in the BLUF input domain result in changes in the downstream output module. Among BLUF proteins with a linked output domain, only two examples of downstream signal transduction events have been described at a molecular level. One example is YcgF from *Escherichia coli* ([@B4], [@B5]) and its homolog BlrP1 in *Klebsiella pneumoniae* ([@B6]) where light excitation of the BLUF domain stimulates phosphodiesterase activity of the EAL output domain that converts c-di-GMP to linear diguanylate ([@B6]). The other example is AppA where light excitation of the BLUF domain inhibits an output domain to function as an antirepressor of the photosystem-specific repressor PpsR ([@B1]).

PpsR in *R. sphaeroides* controls heme, bacteriochlorophyll, and photosynthesis gene expression with the activity of the PpsR-AppA system highly regulated by numerous input signals such as light, redox, and heme ([@B1], [@B7], [@B8]). Several input signals directly affect the activity of PpsR, while others affect the ability of AppA to interact with PpsR. For example, under aerobic growth conditions, two cysteine residues in PpsR are in an oxidized state which stimulates its DNA binding activity ([@B1]). This is contrasted by anaerobic conditions where these cysteines are in a reduced state which impedes DNA binding. PpsR also binds heme via a conserved Cys residue present in the DNA-binding domain and a histidine present in a Per-Arnt-Sim (PAS) domain ([@B7]). Bound heme affects the interaction between PpsR and its target DNA ([@B7]).

The antirepressor AppA consists of an N-terminal BLUF domain that utilizes flavin to sense light, a middle SCHIC (sensor containing heme instead of cobalamin) domain ([@B9]) that binds heme and a redox-responding C-terminal Cys-rich domain ([Fig. 1A](#fig1){ref-type="fig"}). The Cys-rich carboxyl domain is capable of reducing the redox-active Cys in PpsR under dark anaerobic conditions to lower the DNA binding affinity of PpsR ([@B1], [@B8]). Additionally, dark-adapted AppA is able to form a stable PpsR~2~-AppA complex that cannot bind to target DNA sequences ([@B1]). Interestingly, the interaction of AppA with PpsR is inhibited by blue-light absorption of the BLUF domain, a regulatory feature that imparts light control of photosynthesis gene expression ([@B1]). A final aspect of AppA regulation involves binding of heme to the SCHIC domain of AppA that is thought to promote interaction of AppA with PpsR ([@B10]). The SCHIC domain has sequence similarity to the well-characterized vitamin B~12~-binding domain of methyltransferases ([@B9], [@B10]), but unlike methyltransferases, the SCHIC domain differentially binds heme over B~12~ ([@B9], [@B10]).

![AppA binds heme. (A) Domain structure of AppA. (B) UV-visible spectrum of AppA-heme reconstituted under aerobic conditions (the spectrum of AppA with flavin is subtracted). Heme (5 µM) was incubated with 10 µM AppA for at least 20 min before the oxidized spectrum was taken. For the reduced spectrum, 10 mM dithionite was added to the sample of AppA-heme right before the measurement was taken. It should be noted that the oxidized versus reduced spectrum refer to the redox state of heme iron (Fe^3+^ versus Fe^2+^), not the presence of oxygen (aerobic versus anaerobic). Absorbance is shown on both the right and left *y* axes. (C) Dynamics of AppA-heme reconstitution. AppA (12 µM) and 1 µM heme (final concentrations for both) were mixed and monitored in a stopped-flow spectrophotometer in the dark or illuminated with white light. The change in absorbance at 412 nm is shown on the *y* axis. (D) *K*~*d*~ of AppA-heme interaction. Reaction rates at different AppA concentration were fitted with a hyperbola model.](mbo0041316070001){#fig1}

Several research groups have reported that the SCHIC domain binds heme, but the details of this interaction have not been clarified. One study used an AppA variant that had the C-terminal Cys-rich motif replaced with a maltose-binding protein (MBP). Studies with this construct indicated that heme binds to AppA-MBP only in the absence of oxygen and that heme is gradually discoordinated from AppA as the oxygen level increases ([@B9]). A second heme binding study used a His~6~-tagged AppA variant that lacked the BLUF domain (ΔN-AppA-His~6~) ([@B10]). Since neither study tested full-length untagged AppA, it has remained unclear whether oxygen or light has an effect on heme binding to AppA.

In this study, we demonstrate that dark-adapted AppA binds heme better than light-excited AppA does and that heme bound to the SCHIC domain significantly reduces the length of the BLUF photocycle. We also solved the structure of the SCHIC domain and identified the histidine residue that is critical for heme binding. The interaction between AppA and heme is further shown to be affected by the redox state of a disulfide bridge located in the Cys-rich C-terminal region. These results indicate that light, redox, and heme sensing by AppA are integrated in this single protein and that AppA antirepression of PpsR activity in response to alterations in redox, light, and heme is significantly more nuanced and complex than previously reported.

RESULTS {#h1}
=======

AppA binds heme under both anaerobic and aerobic conditions. {#h1.1}
------------------------------------------------------------

We examined the interaction of AppA with heme by purifying tagless full-length AppA from an *E. coli* overexpression system. As previously reported by our group, there were no significant amounts of heme observed when full-length AppA was purified from the *E. coli* overexpression system ([@B1]). However, it does contain flavin adenine dinucleotide (FAD) as the BLUF domain cofactor. To ensure that our experimental conditions covered a wide range of oxygen concentrations, we prepared AppA either in degassed buffer (oxygen level of \<1 mg/liter) or in air-saturated buffer (oxygen level of \>6 mg/liter) for use in interaction studies with heme. Both samples exhibited almost identical absorption spectra, indicating no oxygen-dependent effect on heme binding by full-length tagless AppA (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material). This is in contrast to a previous report that AppA binds to heme only when oxygen is absent ([@B9]). Calculating the amount of heme binding in replicate reconstitution experiments showed that AppA binds heme at a ratio of 1.17 ± 0.07 heme per 1 AppA, further confirming that full-length AppA can bind heme in the presence of oxygen.

Spectral analysis of the full-length AppA-heme complex showed characteristics similar to those previously reported with His~6~-tagged AppA that lacked the BLUF domain and AppA that had the Cys-rich carboxyl domain replaced with a maltose-binding domain ([@B9], [@B10]). The spectrum with ferric (Fe^3+^) heme has a well-defined Soret peak at 412 nm with broad peaks in the 500- to 600-nm region ([Fig. 1B](#fig1){ref-type="fig"}). Reduction of heme iron to Fe^2+^ with 10 mM dithionite yields a Soret peak at 424 nm and α and β peaks at 558 nm and 528 nm, respectively ([Fig. 1B](#fig1){ref-type="fig"}). We also performed stopped-flow analysis to measure the kinetics of heme binding by AppA. After mixing AppA with heme under dark aerobic conditions, the time course of heme binding as measured by monitoring Δ*A*~412~ could be described by a single exponential equation ([Fig. 1C](#fig1){ref-type="fig"}). The heme-binding rate under dark aerobic conditions was fitted with the concentration of AppA, yielding a *K*~*d*~ (dissociation constant) of 1.25 ± 0.44 µM ([Fig. 1D](#fig1){ref-type="fig"}). This rather weak binding affinity is similar to values reported for other heme-sensing proteins such as PpsR (\~1.9 µM) ([@B7]) and R-transferase (\~0.15 µM) ([@B11]).

Light excitation of the BLUF domain impedes heme binding by the SCHIC domain. {#h1.2}
-----------------------------------------------------------------------------

To test whether the light-regulated BLUF domain has a role in regulating SCHIC domain interaction with heme, we monitored the kinetics of heme binding in dark- and light-adapted AppA using stopped-flow analysis. As shown in [Fig. 1C](#fig1){ref-type="fig"}, there is no significant binding of heme to lit AppA observed over the course of the experiment. This is in contrast to dark-adapted AppA that exhibits exponential binding of heme as monitored by amplification of Δ*A*~412~ ([Fig. 1C](#fig1){ref-type="fig"}). This result indicates that AppA binds heme effectively only under dark conditions.

In previous studies, we described several mutations in the BLUF domain (AppA~Y21F~ \[AppA with a Y-to-F change at position 21\] and AppA~Q63E~) that remain in a lit signaling state irrespective of whether these proteins are under dark or illuminated conditions ([@B12], [@B13]). We assayed heme binding with AppA~Y21F~ and AppA~Q63E~ in the dark to confirm whether there is indeed a connection between light sensing and heme binding. As shown in [Fig. 2A](#fig2){ref-type="fig"}, incubation of AppA~Y21F~ and AppA~Q63E~ with heme for 30 min shows that both proteins bind heme very poorly in the dark as evidenced by large amounts of free unbound heme with a peak at 370 nm and only a slight shoulder of bound heme with a peak at 412 nm. This is in contrast to wild-type AppA, which shows excellent binding under similar dark conditions ([Fig. 2A](#fig2){ref-type="fig"}).

![Integration of light sensing and heme binding in AppA. (A) Absorption spectrum of heme and different AppA constructs under aerobic conditions. AppA mutants and heme were mixed at a 2:1 ratio and incubated for at least 20 min before the spectrum was taken. The spectrum of the protein with flavin is subtracted. Normalized absorbance is shown on the right and left *y* axes. (B) Absorption spectrum of AppA and AppA-heme complex in dark (D) and lit (L) states. The spectrum of protein was not subtracted. (C) Differential spectrum of AppA mutants and heme (dark state minus light state). The samples in [Fig. 2A](#fig2){ref-type="fig"} were used here. (D) Recovery kinetics of AppA/AppA-heme light cycle. AppA and AppA-heme complex were light excited and put back in dark conditions. Absorbance at 493 nm was measured to monitor the photocycle of the BLUF domain, and the data were fitted to a single-exponential model.](mbo0041316070002){#fig2}

We also observed that light excitation of the BLUF domain affected the spectrum of prebound heme. In this analysis, light excitation of AppA-heme complex resulted in a slight but reproducible reduction of the Soret peak at 412 nm ([Fig. 2B](#fig2){ref-type="fig"}), which indicates a weakening of AppA-heme interaction. A dark-minus-light differential spectrum of the AppA-heme sample clearly shows this reduction at 412 nm and an alteration of flavin absorbance at the 500-nm region attributed to the BLUF photocycle ([Fig. 2C](#fig2){ref-type="fig"}). Note that similar analysis with BLUF mutants AppA~Y21F~ and AppA~Q63E~ did not show alterations in the Soret peak at 412 nm upon exposure to light, as these mutants are in locked in an illuminated state ([Fig. 2C](#fig2){ref-type="fig"}).

Bound heme pushes the BLUF domain toward the dark state conformation. {#h1.3}
---------------------------------------------------------------------

Given that light excitation of the BLUF domain affects heme binding to the SCHIC domain, we asked whether heme bound to the SCHIC domain inversely affects the state of the BLUF domain. To test this possibility, we measured the BLUF photocycle by monitoring spectral changes in the flavin absorption region. Dark-adapted AppA has a broad flavin absorption peak with a maximum at 450 nm that upon light excitation redshifts \~10 nm as a result of a conformational change in the BLUF domain. This excitation spectral shift subsequently falls back to the ground state with a half-life of \~15 min when the protein returns from a lit to a dark conformation ([@B1]). The dark and lit state flavin absorption spectra show the same spectral features in both AppA and AppA with bound heme indicating that the BLUF domain has the same general conformation whether or not heme is bound ([Fig. 2B](#fig2){ref-type="fig"}). However, the length of the AppA-heme photocycle is considerably shorter, with a decay half-life of \~4 min compared to AppA itself that has a half-life of \~15 min ([Fig. 2D](#fig2){ref-type="fig"}). This indicates that the BLUF domain prefers a dark conformation when heme is bound to the SCHIC domain.

The SCHIC domain uses His^284^ to interact with heme. {#h1.4}
-----------------------------------------------------

We obtained crystals of the SCHIC domain (AppA amino acids 186 to 398) ([Fig. 3A](#fig3){ref-type="fig"}; see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material) without bound heme using hanging drop vapor diffusion. Unfortunately, the SCHIC domain alone does not incorporate heme in stoichiometric amounts, so we were not successful in growing SCHIC crystals containing heme. Due to the inherent problems of heme solubility, we were also unsuccessful in loading heme by soaking protein crystals with heme containing mother liquor. Nevertheless, the solved SCHIC domain apo-structure at 2.04 Å does provide valuable information on a putative heme-binding cleft.

![Crystal structure of SCHIC domain and His^284^ as the heme coordinating residue. (A) Crystal structure of SCHIC domain contains two subunits (subunit A shown in orange, and subunit shown B in light blue). (B) SCHIC domain (subunit A \[orange\]) shares similar overall conformation with *E. coli* MetH B~12~-binding domain (green). The His loop in MetH is highlighted in magenta, and the vitamin B~12~ molecule is shown as purple sticks. Subunit A of SCHIC domain is used for the structure comparison. (C) His^284^ in SCHIC (orange) and His^759^ in MetH (green) are located on the His loop region. Note the differences in their positions and orientations. (D) UV-visible spectrum of AppA-heme and AppA~H284A~-heme under aerobic conditions. The spectrum of AppA/AppA~H284A~ is subtracted. Heme (5 µM) was incubated with 10 µM AppA/AppA~H284A~ for at least 20 min before the spectrum was taken. Normalized absorbance is shown on both the right and left *y* axes.](mbo0041316070003){#fig3}

The crystal lattice contains two copies of a homodimeric SCHIC domain that have similar conformations with a root mean square deviation (RMSD) of 0.40 Å between the dimers. Individual subunits are comprised of an N-terminal helix bundle followed by a C-terminal α/β Rossmann fold ([Fig. 3A](#fig3){ref-type="fig"}). As shown in [Fig. 3B](#fig3){ref-type="fig"}, the SCHIC structure superposes very closely with the vitamin B~12~-binding domain from methionine synthase (MetH, 1BMT.pdb) ([Fig. 3B](#fig3){ref-type="fig"}) ([@B14]). The MetH-B~12~ structure contains a well-defined B~12~-binding cleft, with a loop where a highly conserved histidine residue directly coordinates with the cobalt in B~12~ ([Fig. 3C](#fig3){ref-type="fig"}) ([@B14]). The SCHIC domain also contains a similar loop with a potential iron-coordinating histidine (His^284^) located 2 amino acids further down this loop than for the cobalt-coordinating histidine present in MetH-B~12~ ([Fig. 3C](#fig3){ref-type="fig"}). The imidazole ring in SCHIC His^284^ is also rotated and moved with an average distance of 6.4 Å from the His^759^ present in MetH ([Fig. 3C](#fig3){ref-type="fig"}). To test whether heme forms a ligand to His^284^, we mutated His^284^ to alanine within full-length AppA and then spectrally analyzed the ability of the mutant peptide to bind heme. Incubation of AppA~H284A~ with heme showed a peak at 370 nm, which is the spectral characteristic of free unbound heme compared to the 412-nm Soret peak of heme bound to wild-type AppA ([Fig. 3D](#fig3){ref-type="fig"}). This observation indicates that the Ala substitution disrupted heme and that His^284^ indeed coordinates with the heme iron.

A disulfide bond in the Cys-rich motif affects the SCHIC-heme interaction. {#h1.5}
--------------------------------------------------------------------------

Even though full-length AppA is capable of binding heme in the presence of molecular oxygen, this result does not rule out that changes in the redox state of the Cys-rich C-terminal domain can affect heme binding. Previous studies from our laboratory have shown that AppA contains a single redox active pair of cysteines that function as a dithiol/disulfide couple with a midpoint potential (*E*~*m*~) of −325 mV ([@B8]). This potential is very similar to the *E*~*m*~ −320 mV potential of a disulfide pair in PpsR that AppA is capable of reducing ([@B1], [@B8]). To determine which cysteines are redox active, we performed matrix-assisted laser desorption ionization−time of flight (MALDI-TOF) analysis of trypsin-digested iodoacetamide (IAM)-labeled AppA. The tryptic peptide AppA~397-409~ was further analyzed using liquid chromatography coupled to electrospray ionization tandem mass spectrometric analysis (LC-ESI-MS-MS) which shows the presence of a Cys^399^--Cys^406^ disulfide bridge ([Fig. 4](#fig4){ref-type="fig"}; see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material).

![The disulfide bridge in the Cys-rich motif affects the SCHIC-heme interaction. (A) A disulfide bridge was identified within peptide AppA~397-409~. Under oxidized conditions, neither Cys^399^ nor Cys^406^ can be modified by iodoacetamide (IAM). Under reduced conditions, the disulfide bridge formed between Cys^399^ and Cys^406^ is reduced, and both residues can be modified by iodoacetamide (DTT-IAM). (B) LC-MS-MS with double-labeled AppA identified the Cys^399^-Cys^406^ disulfide bond (see [Fig. S2](#fig2){ref-type="fig"} in the supplemental material). (C) The cysteine residues in AppA are reduced by DTT (AppA~R~). When light excited, the Soret peak of AppA~R~-heme is redshifted from 412 nm to 418 nm. (D) When light excited, the Soret peak of AppA~C399A~-heme is redshifted from 412 nm to 418 nm.](mbo0041316070004){#fig4}

To address whether the Cys^399^--Cys^406^ disulfide bond affects the AppA-heme interaction, we reduced the disulfide bond with dithiothreitol (DTT) and then analyzed the heme spectrum. The heme spectrum of reduced AppA exhibits a normal Soret peak at 412 nm in the dark state. However, when the BLUF domain is light excited, the heme Soret peak in reduced AppA exhibits a 6-nm redshift along with a decrease in intensity ([Fig. 4C](#fig4){ref-type="fig"}). This is distinctly different than that of oxidized wild-type AppA where the heme Soret peak decreases without a redshift upon light excitation ([Fig. 2B](#fig2){ref-type="fig"}). To confirm that this effect is a result of the reduced disulfide bridge, we constructed a Cys^399^-to-Ala point mutation. Purified AppA~C399A~ also exhibited the same 6-nm redshift along with a decrease in intensity as described above for reduced AppA ([Fig. 4D](#fig4){ref-type="fig"}). Interestingly, AppA with a Cys^406^ Ala mutation (the other residue of the disulfide pair) exhibited a dark/light spectrum that is similar to the spectrum of oxidized wild-type AppA ([Fig. 5A](#fig5){ref-type="fig"}). Further analysis showed that a disulfide bond can form between Cys^399^ and a neighboring Cys (Cys^405^) in this construct ([Fig. 5B](#fig5){ref-type="fig"}), which appears to function like the original Cys^399^--Cys^406^ disulfide bond present in wild-type AppA. Taken together, these results indicate that the presence of a disulfide bridge in the Cys-rich motif has an effect on the heme binding properties of the SCHIC domain.

![(A) When light excited, the Soret peak of AppA~C406A~-heme remains at 412 nm (indicated by the vertical broken black line). (B) A disulfide bond exists in peptide AppA~397-409~ in the AppA~C406A~ construct which can only be Cys^399^-Cys^405^. (C) Dynamics of AppA~C399A~-heme reconstitution. (D) Dynamics of AppA~C406A~-heme reconstitution.](mbo0041316070005){#fig5}

The effect of this reduced disulfide on heme binding can also be demonstrated by assaying absorbance changes using stopped-flow experiments. As discussed above, heme binding with wild-type AppA can be analyzed by stopped-flow analysis by measuring the rise in absorbance at 412 nm that can be described in a single exponential equation ([Fig. 1C](#fig1){ref-type="fig"}). Loss of the Cys^399^--Cys^406^ disulfide bridge in AppA~C399A~ results in a similar rapid rise at 412 nm, followed first by a short plateau and then by a slow decrease of the Soret peak ([Fig. 5C](#fig5){ref-type="fig"}). As is the case of wild-type AppA, AppA~C406A~, which forms the alternative Cys^399^--Cys^405^ disulfide bond, does not exhibit a slow decrease in the Soret peak after binding heme ([Fig. 5D](#fig5){ref-type="fig"}). We interpret this result as evidence that the binding of heme in reduced AppA first involves the formation of the 412-nm Soret spectral species followed by slow decay to an alternate state that is capable of undergoing the 6-nm redshift upon light excitation of the BLUF domain.

Finally, as discussed earlier, the presence of heme in AppA that has Cys^399^--Cys^405^ in its oxidized disulfide state shortens the BLUF photocycle half-life to \~4 min, which is significantly faster than the 15-min half-life observed with oxidized AppA that does not contain heme ([Fig. 2D](#fig2){ref-type="fig"}). Interestingly, heme-induced reduction of the BLUF photocycle is absent when the disulfide in AppA is reduced with DTT. Under this condition, the photocycle half-life is \~11 min with or without bound heme. The latter result suggests that the redox state of this disulfide affects signal communication between the BLUF domain and the heme-binding SCHIC domain.

DISCUSSION {#h2}
==========

Numerous studies show that *Rhodobacter sphaeroides* uses the PpsR-AppA regulatory system to coordinate biosynthesis of heme and bacteriochlorophyll with synthesis of photosystem apoproteins ([@B1], [@B15], [@B16]). In this study, we demonstrate that tagless full-length AppA can bind heme under both anaerobic and aerobic conditions ([Fig. 1B](#fig1){ref-type="fig"}). This finding is in contrast to a report by Moskvin et al. ([@B9]), which indicated that oxygen can discoordinate heme from AppA in a concentration-dependent manner. This apparent difference likely stems from the fact that our study utilized full-length tagless AppA, while the study by Moskvin et al. utilized an MBP-tagged AppA that also contained a truncation of the Cys-rich motif.

If heme is not an oxygen sensor, then what is its function when it is bound to the SCHIC domain of AppA? The absorption characteristics of the flavin region in both dark and light states are identical with or without bound heme, indicating that the BLUF domain undergoes a similar hydrogen bond rearrangement in the presence or absence of heme ([Fig. 2B](#fig2){ref-type="fig"}). However, the length of the AppA photocycle is dramatically reduced when oxidized AppA contains bound heme relative to that observed with AppA alone. The consequence of a quicker photocycle is that it would increase the population of AppA that is present in the dark state. Given that only AppA in the dark state is capable of interacting with PpsR, the binding of heme would therefore increase the antirepressor activity of AppA on PpsR ([Fig. 6A](#fig6){ref-type="fig"}). This would result in increased bacteriochlorophyll and light-harvesting gene expression to promote maximal synthesis of the photosystem ([Fig. 6B](#fig6){ref-type="fig"}). The involvement of heme in controlling the AppA photocycle appears to be a means to ensure that increased synthesis of the photosystem does not occur unless there is sufficient heme available to handle the essential function of electron transfer. In purple bacteria, cytochrome biosynthesis is essential, while synthesis of the photosystem is not. Furthermore, electrons derived from photosynthesis need to be shuttled back to the photosystem via heme-containing cytochromes. Consequently, it is not surprising that heme has a role in controlling the amount of photosystem synthesis via the regulation of AppA activity.

![Proposed model of heme function. (A) Dark-adapted AppA can form the PpsR~2~-AppA complex and inactivate PpsR, thus enhancing the target gene transcription. When light excited, AppA is incapable of interacting with PpsR, leaving PpsR bound to its target DNA. The presence of heme pushes AppA toward its dark state and thus promotes the formation of the PpsR~2~-AppA complex. (B) Diagram of tetrapyrrole biosynthesis and photosynthesis. The presence of heme could potentially redirect the flow of 5-aminolevulinic acid (ALA) away from the heme branch and into the bacteriochlorophyll branch. Urogen III, uroporphyrinogen III; Proto IX, protoporphyrin IX.](mbo0041316070006){#fig6}

The solved crystal structure of the SCHIC domain shows remarkable sequence similarity with the vitamin B~12~-binding domain in MetH ([@B9], [@B10]). Heme and vitamin B~12~ have significant different structures and central metals. For example, heme *b* has methyl and formyl side groups with the bound iron free to form axial ligands. This is in contrast to vitamin B~12~ where the corrin ring has 7 propionamide side groups and 2 alcohol side groups as well as a bulky attached dimethylbenzimidazol ribonucleotide group that forms a lower axial ligand to the bound cobalt. B~12~ also contains a second upper axial cobalt (Co) ligand typically comprised of a methyl or 5′-deoxyadenosine group. Thus, it is surprising that the crystal structure of the SCHIC domain is so similar to the structure of the B~12~-binding domain from MetH ([Fig. 2B](#fig2){ref-type="fig"}).

Despite these similarities, there are several subtle changes that likely contribute to tetrapyrrole selectivity ([Fig. 7A](#fig7){ref-type="fig"}). For example, the loop in MetH that forms a lower axial ligand of His to Co is altered in the SCHIC structure such that the His is displaced by two residues ([Fig. 3C](#fig3){ref-type="fig"}). In addition, MetH-B~12~ has Phe^708^ and Leu^715^ located at one end of the second helix in the helix bundle that serves as a cap to cover the reactive methyl ligand of cobalamin (met cap) ([@B14]). Located in a similar position of this helix in the SCHIC structure is Leu^239^ and a positive charged Arg^246^ that are in contact with a loop extended from the Rossmann fold (extension) ([Fig. 7B](#fig7){ref-type="fig"}). These changes would block the binding of Met- or Adeno-B~12~ to the SCHIC domain ([Fig. 7C](#fig7){ref-type="fig"}). This extension also forms a hydrogen bond network with the His loop in the SCHIC domain that locks the orientation of Fe-binding His^284^ in a position (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material) that is distinct from the Co-coordinating His^759^ in MetH-B~12~ ([@B14]). Finally, there is additional space in the core of the MetH-B~12~ Rossmann fold that anchors the bulky attached nucleotide tail of vitamin B~12~ ([@B14]). In the SCHIC domain, the access to this docking space is blocked by Glu^289^ which resides on the His loop (dock lock \[[Fig. 7B and D\]](#fig7){ref-type="fig"}). These changes likely constitute selectivity of these similar tetrapyrrole binding domains for heme versus B~12~.

![Architectural basis of heme/B~12~ differentiation. (A) Sequence alignment of AppA SCHIC and selected MetH vitamin B~12~-binding domains. Three sequences, the *R*. *sphaeroides*, *Rhodobacter capsulatus*, and *E*. *coli* sequences, are shown. The MetH B~12~-binding domains were aligned first. Residues that are identical, highly similar, or less similar were shown with black, medium gray, or light gray background, respectively. The alignment was then compared to the SCHIC sequence based on sequence and structure homology. The regions in AppA SCHIC domain that are critical for heme/B~12~ differentiation are shown on a red background. (B) Crystal structure of SCHIC domain (subunit A). Regions critical for heme/B~12~ differentiation other than the His loop are highlighted as followed: extension (blue), met cap (red), and dock lock (yellow). (C) Structure of the extension and met cap regions in SCHIC (orange) and MetH (green). Note that these two regions are in contact in SCHIC (orange) (hydrogen bond between R^246^ and L^334^) but far away from each other in MetH (green). The contact in SCHIC would block the B~12~ binding cleft in MetH (broken green line). (D) Structure of the dock lock in SCHIC (orange) and MetH (green). Note that E^289^ occupies more space in SCHIC (orange) than G^762^ does in MetH (green). (E) The extension loop in SCHIC is flexible and interacts differently with the met cap and His^284^ in molecule A (orange) and molecule B (blue) in the crystallographic dimer. The detailed hydrogen networks are shown in [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material.](mbo0041316070007){#fig7}

Interestingly, the described regions critical for heme/B~12~ differentiation map to an extension in the SCHIC domain Rossmann fold that exhibit different conformations in the two subunits of the SCHIC crystal structure ([Fig. 7B and E](#fig7){ref-type="fig"}). In one subunit, part of this extension is moved \~7 Å, forming different interactions with the methyl cap and the His loop (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material). This could represent the "empty" state versus an "en route" position toward heme-bound conformation. As a heme-sensing module, SCHIC is probably not at its most stable state with and without bound heme, since it does not bind heme tightly. This might explain our failure to grow crystals of SCHIC-heme complex or to reconstitute SCHIC crystals with heme.

While this article was under review, several truncated structures of AppA and PpsR were also published by Winkler et al. ([@B17]). A co-complex of the SCHIC domain to a truncated region of PpsR that contained the amino terminus through the first PAS domain was obtained. This suggests that the SCHIC domain interacts with this region of PpsR ([@B17]). What remains unknown is the structure of the Cys-rich C terminus of AppA and the structures of full-length AppA and PpsR proteins. The Cys-rich domain of AppA contains six cysteine residues within a 21-amino-acid stretch that has a sequence pattern similar to Cys-rich motif found in granulin, a protein critical for neurodegeneration ([@B18], [@B19]), as well as several plant proteases ([@B20]--[@B23]). The solution structure of carp granulin-1 shows a hairpin stack fold that is stabilized by disulfide bridges ([@B19]). The redox-active cysteines in the region are thought to reduce the redox-active Cys in PpsR, which affects its DNA binding activity. Our results provide evidence that the redox state of AppA Cys-rich motif can affect signal transfer between the light-sensing BLUF domain and the heme-sensing SCHIC domain. The structures of full-length AppA and/or the intact PpsR-AppA complex will be necessary to determine how AppA is able to control the redox state of PpsR and to form a complex that inhibits its activity.

MATERIALS AND METHODS {#h3}
=====================

Strains, media, and growth conditions. {#h3.1}
--------------------------------------

Strain BL21(DE3) (Novagen) was used for protein overexpression in *E. coli*. Luria broth (LB) was used for agar-solidified plates and liquid cultures for *E. coli*. The antibiotics used and their final concentrations were as follows: ampicillin, 100 µg ml^−1^; kanamycin, 50 µg ml^−1^ for agar-solidified plates and 25 µg ml^−1^ for liquid cultures.

Plasmid construction. {#h3.2}
---------------------

Wild-type AppA, AppA Cys mutants (AppA~C399A~ and AppA~C406A~) and AppA His mutants (AppA~H284A~, AppA~H308A~, and AppA~H386A~) were expressed in *E. coli* using modified small ubiquitin-like modifier SUMO-I (LifeSensors Inc.) overexpression system. The coding region was cloned from pTY-AppA ([@B24]) and inserted into the NdeI*-*NotI restriction sites of pSUMO. The pTY-AppA plasmid was subjected to site-directed mutagenesis (Herculase II; Stratagene) to create point mutations in the BLUF domain (AppA~Y21F~ and AppA~Q63E~). All point mutations were created by the standard QuikChange (Agilent Technologies) protocol.

Protein purification for biochemical experiments. {#h3.3}
-------------------------------------------------

SUMO-tagged full-length AppA was overexpressed and purified as described previously ([@B7]). Proteins cloned into the pTY plasmid (AppA~Y21F~ and AppA~Q63E~) were purified using chitin beads and the manufacturer's protocol (New England Biolabs) followed by gel filtration chromatography using Sephacryl S-200 HP resin (GE Healthcare). All purified proteins were purified in a buffer of 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 5% glycerol, and all experiments were performed in the same buffer unless otherwise noted.

Protein-heme interactions. {#h3.4}
--------------------------

Heme reconstitution with AppA and AppA mutants was performed as described previously ([@B7]). The sample was either degassed or air bubbled when needed with dissolved oxygen concentration measured using an oxygen CHEMets kit (CHEMetrics). UV-visible absorption spectrum was recorded using a Beckman DU 640 spectrophotometer as described previously ([@B7]). To convert AppA into a light-excited state, dark-adapted samples were illuminated with strong white light for 30 s immediately before spectral analysis unless noted otherwise. Note that the heme spectrum itself stays identical in dark and illuminated conditions (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material).

Purification of SCHIC for crystallization. {#h3.5}
------------------------------------------

To construct an SCHIC domain expression vector, AppA with amino acids 186 to 398 (AppA~186-398~) was cloned into pTYB12 plasmid (New England BioLabs) with NotI-NdeI sites. *E*. *coli* BL21(DE3) cells were freshly transformed, grown on autoinducing medium LBE-5052 ([@B25]) for 3 h at 37°C, and then transferred to 16°C for protein expression overnight. Cells were collected and resuspended in chitin binding buffer (50 mM HEPES \[pH 7.0\], 50 mM NaCl, 0.2 mM EDTA) and lysed using the cell cracker. After centrifugation, the cell extract was passed through chitin beads at room temperature, and the cleavage of chitin tag was initiated with fresh 50 mM DTT in the chitin binding buffer. The next day, tagless protein was eluted and loaded onto Superose 12 for the final purification step. The final buffer was 50 mM HEPES and 400 mM NaCl. Pure (\>95%) and soluble protein was obtained and concentrated to \~15 mg/ml for crystallization.

Crystallization of SCHIC. {#h3.6}
-------------------------

The purified SCHIC was first screened for potential crystallization conditions using the Index screen by Hampton Research. The Index screen provided initial hits (e.g., N 70, 71, 78, and 79), and we refined the original condition 71 to obtain single crystals. The crystals grew within a few days to \~0.1 to 0.2 mm but were very unstable when cryoprotectants were tested. Therefore, an attempt to add a cryoprotectant in the crystallization buffer was made, and we obtained crystals in 23% polyethylene glycol PEG 3350, 10% glycerol, Bis-Tris (pH 6.0), and 0.2 M NaCl that were suitable for immediate freezing and data collection.

Growing SCHIC protein on minimal medium and selenomethionine. {#h3.7}
-------------------------------------------------------------

For phasing purposes, we grew SCHIC on the M9 minimal medium containing 100 mg/liter of selenomethionine and amino acid mixture that inhibits methionine synthesis (F, K, T, V, L, and I). The cells were slower to grow and once induced with 1 mM isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG), the synthesis of protein with selenomethionine was allowed to proceed for 24 h. Purification proceeded as described above, and the best crystals grew in the same condition as native crystals; however, to prevent oxidation of selenium, we added 5 mM DTT to the crystallization buffer.

Data collection and processing. {#h3.8}
-------------------------------

Diffraction data were collected at the Berkeley beamline Advanced Light Source (ALS) 4.2.2. using remote data collection. The best anomalous data set was collected using selenium peak (4 selenium atoms in the SCHIC molecule) at 2.2-Å resolution. Data collection proceeded for 210° with a step of 1°. The crystal mosaicity was \~0.8. The best diffraction native data set was collected at 2.05-Å resolution. Initial indexing by HKL2000 provided primitive monoclinic space group P21. The initial phase estimates using SeMet data set were computed using Phaser ([@B26]). Autobuild software of Phenix ([@B27]) then provided the beginning model. Coot ([@B28]) and Phenix were used for model building and final refinement. Final refinement statistics are shown in [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material.

Stopped-flow spectroscopy. {#h3.9}
--------------------------

Dynamics of the AppA-heme reaction was measured using a KinTek stopped-flow SF-300 instrument. Various concentrations of AppA and heme were mixed in the reaction chamber with absorbance at 412 nm monitored. For analysis of the reaction of heme with dark state AppA, AppA was kept in the dark for at least 20 min before the reaction was initiated. For the reaction of heme with lit state AppA, dark state AppA was loaded into a clear glass injection syringe and then illuminated for at least 20 s before and during the time course of the monitored reaction. The *K*~*d*~ of AppA-heme interaction was calculated using the standard model as reported before ([@B29]).

Mapping cysteine residues in AppA. {#h3.10}
----------------------------------

The presence of reduced Cys sulfhydryl residues in AppA was determined by incubating \~10 µM AppA (either oxidized or 10 mM DTT-reduced) with 10 or 20 mM iodoacetamide at 22° C for 10 min. Excess iodoacetamide was then removed by passing through a MidiTrap G-25 (GE Healthcare) desalting column or a Zeba spin desalting column with a molecular weight cutoff of 7,000 (7K MWCO) (Thermo Scientific), depending on the sample volume. The samples were then treated with trypsin (protein/trypsin ratio is 10:1) at 37°C overnight. The digestion was stopped by the addition of trifluoroacetic acid (TFA) to a final concentration of 0.1% and desalted using ZipTip pipettes with C18 resin (Millipore). The samples eluted from ZipTip pipettes by 60% acetonitrile and 0.1% TFA were used for MALDI experiments with a Bruker Autoflex III MALDI-TOF mass spectrometer. To determine which cysteine residues are forming a disulfide bridge, 5 µM AppA was treated with 5 mM *N*-ethylmaleimide (NEM) for 45 min at 22°C, then with 10 mM DTT for 10 min at 22°C, and finally with 20 mM iodoacetamide for 30 min at 22°C. The double-labeled tryptic digest was analyzed by capillary-scale liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) ([@B30]). An Eksigent two-dimensional (2D) Ultra liquid chromatograph (AB Sciex, Foster City, CA) injected 5 µl of extract onto a trapping column (100 by 0.1 mm) packed with 5-µm Michrom Magic C18 particles and desalted for 8 min at a flow rate of 4 µl/min using LC buffer A (0.1% \[vol/vol\] formic acid \[Sigma-Aldrich\], 3% \[vol/vol\] acetonitrile \[EM Science\] in high-performance liquid chromatography \[HPLC\]-grade water \[EM Science\]). The trapping column was then placed in line with a Picofrit column (150 by 0.075 mm) with an integrated ESI tip (New Objective, Woburn, MA) packed with the same material as in the trap. A 35-min gradient from 10 to 85% LC buffer B (0.1% \[vol/vol\] formic acid, 3% \[vol/vol\] water in acetonitrile) separated the peptide mixture prior to tandem mass spectrometry in an LTQ-Orbitrap XL mass spectrometer (Thermo, Waltham, MA). The mass/charge ratios of the intact peptide ions were measured at a resolving power of 15,000 in the orbitrap; the fragment ions were generated, and their masses were measured in the LTQ ion trap. The resulting mass spectra were manually interpreted; the MS-Product module of ProteinProspector (<http://prospector.ucsf.edu>) ([@B31]) was used to predict the fragment ion masses.

Protein structure accession number. {#h3.11}
-----------------------------------

The final structure has been deposited in the Protein Data Bank (PDB) under accession number 4HEH.

SUPPLEMENTAL MATERIAL {#h4}
=====================

###### 

UV-visible spectrum of AppA-heme under aerobic (A) and anaerobic (B) conditions. Heme (5 µM) was incubated with 10 µM AppA for at least 20 min before the spectrum was taken. Download

###### 

Figure S1, TIF file, 10.1 MB

###### 

The ESI−collision-induced dissociation (CID) ([@B30]) tandem mass spectrum of the tryptic peptide VAC^399^PANADC^405^C^406^SMR from the AppA protein after the double labeling experiment. The observed b-type and y-type fragment ions ([@B32]) are labeled (b ions from the N terminus and y ions from the C terminus). The inset shows the mass spectrum of the intact peptide ion prior to fragmentation. The charge state is +2 based on the isotope spacing, and the observed monoisotopic mass/charge ratio is within 2.1 ppm of the predicted value (790.3097) for the indicated peptide structure. The y~4~ and y~5~ ions have mass/charge ratios of 553.2 Thomson (Th) and 781.3 Th, respectively, and these are within 0.1 Th of those predicted given the peptide sequence shown in the figure. The mass of fragment y4 specifically indicates that Cys^406^ has a 57.02-Da adduct (from iodoacetamide added after disulfide reduction); the mass of y~5~ infers that Cys^405^ has a 125.05-Da adduct (from *N*-ethylmaleimide added prior to disulfide reduction). The mass of ion b3 (331.1 Th) is consistent with Cys^399^ modified by iodoacetamide. These results combined with the MALDI data in [Fig. 4B](#fig4){ref-type="fig"} demonstrate that a disulfide bond existed between Cys^399^ and Cys^406^ while Cys^405^ was a free thiol when the protein was isolated. Download

###### 

Figure S2, TIF file, 3.3 MB

###### 

Hydrogen bond network in SCHIC extension region. (A) Hydrogen bond network around the extension loop in SCHIC crystal structure chain A. (B) Hydrogen bond network around extension loop in SCHIC crystal structure chain B. Download

###### 

Figure S3, TIF file, 6.9 MB

###### 

Absorption spectrum of heme in dark and lit states. Download

###### 

Figure S4, TIF file, 3.3 MB

###### 

Refinement statistics of SCHIC domain structure. The RCSB PDB accession number of the native SCHIC domain is 4HEH.

###### 

Table S1, DOCX file, 0.1 MB.
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